Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 97

Sort by

Sort Order Select

Journal Articles

Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

Tim H Brümmendorf, MD, Jorge E. Cortes, MD, Dragana Milojkovic, Carlo Gambacorti-Passerini, MD, Richard E. Clark, MA, MD MRCP, FRCPath, Philipp D le Coutre, MD, Valentín Garcia-Gutiérrez, MD PhD, Charles Chuah, MD, Vamsi Kota, MD, Jeffrey H. Lipton, MD PhD, Philippe Rousselot, MDPhD, Michael J. Mauro, MD, Andreas Hochhaus, MD, Rafael Hurtado Monroy, MD, Eric Leip, Simon Purcell, Anne Yver, PharmD, Andrea Viqueira, MD, Michael W. Deininger, MD PhD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-137393

Published: 2020

Journal Articles

Prevalence of Inherited Predisposition Syndromes in Young Patients with Acute Myeloid Leukemia and Aberrant Karyotype

Martin Kirschner, Benjamin Rolles, MD, Martina Crysandt, Christoph Röllig, Prof., MD, Friedrich Stolzel, MD, Martin Bornhäuser, MD, Carsten Müller-Tidow, MD, Kim Kricheldorf, Margherita Vieri, PhD, Matthias Begemann, Angela Maurer, Jens Panse, MD, Susanne Isfort, Marcin Wlodarski, MD PhD, Sushree Sangita Sahoo, PhD, Tim H Brümmendorf, MD, Edgar Jost, Fabian Beier, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-142815

Published: 2020

Journal Articles

Interplay between PI3K/mTOR Signaling and IRE1a-XBP1 Promotes Survival of Pre-B NRAS G12D all Cells Providing a Therapeutic Vulnerability for the "Undruggable" Driver RAS

Iris Appelmann, MD, Azam Salimi, Michael Huber, PhD, Mirle Schemionek, PhD, Margherita Vieri, PhD, Tim H Brümmendorf, MD, John B. Patterson, Behzad Kharabi Masouleh, MD

Blood (2020) 136 (Supplement 1): 47–48.

https://doi.org/10.1182/blood-2020-140299

Published: 2020

Journal Articles

Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial

Jorge E. Cortes, MD, Philipp D le Coutre, MD, Carlo Gambacorti-Passerini, MD, Henrik Hjorth-Hansen, MD, Pia Raanani, MD, Valentín Garcia-Gutiérrez, MD PhD, Vamsi Kota, MD, Simon Purcell, Andrea Viqueira, Eric Leip, Tim H Brümmendorf, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-134912

Published: 2020

Journal Articles

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

Blood (2019) 134 (Supplement_1): 666.

https://doi.org/10.1182/blood-2019-127127

Published: 2019

Journal Articles

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

B. Douglas Smith, MD, Tim H Brümmendorf, MD, Gail J. Roboz, MD, Carlo Gambacorti-Passerini, MD, Aude Charbonnier, Andrea Viquiera, Eric Leip, PhD, Frank Giles, MD, Thomas Ernst, MD, Andreas Hochhaus, MD, Gianantonio Rosti, MD

Blood (2019) 134 (Supplement_1): 1650.

https://doi.org/10.1182/blood-2019-122230

Published: 2019

Journal Articles

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Christoph Röllig, MD MSC, Michael Kramer, M.Sc., Christoph Schliemann, Jan-Henrik Mikesch, MD, Björn Steffen, MD, Alwin Krämer, MD, Tim Sauer, MD, Mathias Hänel, MD, Regina Herbst, MD, Kerstin Schäfer-Eckart, MD, Richard Noppeney, MD, Edgar Jost, MD, Tim H Brümmendorf, MD, Stefan W Krause, MD, Volker Kunzmann, MD PhD, Hermann Einsele, MD, Sebastian Scholl, Andreas Hochhaus, MD, Lars R. Fransecky, MD, Martin Kaufmann, MD, Andreas Neubauer, MD, Dirk Niemann, MD, Markus Schaich, MD, Norbert Frickhofen, MD, Alexander Kiani, Frank Heits, MD, Ulrich Krümpelmann, Ulrich Kaiser, MD, Johannes Kullmer, Maxi Wass, MD, Stefan Klein, MD, Malte Von Bonin, Jan Moritz Middeke, MD, Christian Thiede, MD, Friedrich Stoelzel, MD, Johannes Schetelig, MDMSc, Gerhard Ehninger, MD, Claudia D Baldus, Carsten Müller-Tidow, MD, Uwe Platzbecker, Hubert Serve, MD, Martin Bornhäuser, MD

Blood (2019) 134 (Supplement_1): 13.

https://doi.org/10.1182/blood-2019-123717

Published: 2019

Journal Articles

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

Blood (2019) 134 (Supplement_1): 1647.

https://doi.org/10.1182/blood-2019-129710

Published: 2019

Journal Articles

STAT1 Transcriptional Response Predicts Molecular Responses of PB-Derived Clonogenic Cells from MPN Patients to Interferon Alpha

Milena Kalmer, MSc, Kristina Feldberg, Deniz Gezer, Susanne Isfort, Tim H Brümmendorf, MD, Nicolas Chatain, Steffen Koschmieder

Blood (2019) 134 (Supplement_1): 1679.

https://doi.org/10.1182/blood-2019-122676

Published: 2019

Journal Articles

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Carlo Gambacorti-Passerini, MD, Tim H Brümmendorf, MD, Bjorn T. Gjertsen, MD PhD, Camille Abboud, MD, Gianantonio Rosti, MD, Elisabetta Abruzzese, MD, Eric Leip, PhD, Andrea Viqueira, MD, Valentín García Gutiérrez, PhD, Frank Giles, MD, Andreas Hochhaus, MD

Blood (2019) 134 (Supplement_1): 2936.

https://doi.org/10.1182/blood-2019-121813

Published: 2019

Journal Articles

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

Steffen Koschmieder, Susanne Isfort, Dominik Wolf, Univ. Prof. Dr., Florian H. Heidel, Philippe Schafhausen, Martin Griesshammer, MD, Denise Wolleschak, Uwe Platzbecker, Konstanze Döhner, Philipp J. Jost, MD, Stefani B. Parmentier, Nikolas von Bubnoff, Frank Stegelmann, MD, Angela Maurer, Jeremy Franklin, Martina Crysandt, MD, Deniz Gezer, Martin Hellmich, Tim H Brümmendorf, MD

Blood (2019) 134 (Supplement_1): 2944.

https://doi.org/10.1182/blood-2019-123985

Published: 2019

Journal Articles

Deconstructing the Clonal Advantage and Clonal Stability of 5q- Candidate Genes in Del(5q) MDS on a Single Cell Level

Ursula S.A. Stalmann, MD, Fabio Ticconi, MSc, Ronghui Li, MSc, Aaron B. Wong, PhD, Glenn Cowley, PhD, David E. Root, PhD, Dirk Heckl, PhD, Inge Snoeren, MSc, Sergio Martinez, PhDMSc, Tim H Brümmendorf, MD, Andreas Schuppert, PhD, Ivan Costa, PhD, Benjamin L. Ebert, MD PhD, Rebekka K. Schneider, MD PhD

Blood (2019) 134 (Supplement_1): 559.

https://doi.org/10.1182/blood-2019-122588

Published: 2019

Journal Articles

Nilotinib Vs Nilotinib Plus Pegylated Interferon α (Peg-IFN) Induction and Nilotinib or Peg-IFN Maintenance Therapy for Newly Diagnosed BCR-ABL1 Positive Chronic Myeloid Leukemia Patients in Chronic Phase (TIGER Study): The Addition of Peg-IFN Is Associated with Higher Rates of Deep Molecular Response

Blood (2019) 134 (Supplement_1): 495.

https://doi.org/10.1182/blood-2019-130043

Published: 2019

Journal Articles

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia

Tim H Brümmendorf, MD, Carlo Gambacorti-Passerini, MD, Camille Abboud, MD, Justin M. Watts, MD, Gianantonio Rosti, MD, Alexander Russell-Smith, Andrea Viqueira, MD, Arlene Reisman, Frank Giles, MD, Andreas Hochhaus, MD

Blood (2019) 134 (Supplement_1): 4157.

https://doi.org/10.1182/blood-2019-124344

Published: 2019

Journal Articles

Common Variable Immunodeficiency (CVID) in Adults As First Manifestation of (cryptic) Dyskeratosis Congenita

Benjamin Rolles, MD, Alla Bulashevska, PhD, Michele Proietti, MD, Sigune Goldacker, MD, Klaus Warnatz, MD, Nadezhda Camacho-Ordonez, MD, Margherita Vieri, MSc, Martin Kirschner, MD, Tim H Brümmendorf, MD, Bodo Grimbacher, MD, Fabian Beier, MD

Blood (2019) 134 (Supplement_1): 1217.

https://doi.org/10.1182/blood-2019-128915

Published: 2019

Journal Articles

Androgen Derivatives Improve Blood Counts and Elongate Telomere Length in Patients with Dyskeratosis Congenita

Martin Kirschner, MD, Monica Sofia Ventura Ferreira, PhD, Anne-Sophie Bouillon, MD, Marcin W. Wlodarski, MD PhD, Michaela Schwarz, MD, Stefan Balabanov, MD PhD, Stefan Wilop, MD, Steffen Koschmieder, MD, Jens P. Panse, MD, Tim H. Brümmendorf, MD, Fabian Beier, MD

Blood (2018) 132 (Supplement 1): 2585.

https://doi.org/10.1182/blood-2018-99-118197

Published: 2018

Journal Articles

Comparison of Fluorescence in Situ Hybridization and Flow Cytometry (Flow-FISH) with Monochrome Multiplex Quantitative Polymerase Chain Reaction (MM-qPCR) for Telomere Length Screening in Adult Patients with Suspected Cryptic Dyskeratosis Congenita (DKC)

Monica Sofia Ventura Ferreira, PhD, Natalia Estrada, Martin Kirschner, MD, Blanca Xicoy, Anne-Sophie Bouillon, MD, Stefan Wilop, MD, Steffen Koschmieder, MD, Jens P. Panse, MD, Tim H. Brümmendorf, MD, Fabian Beier, MD

Blood (2018) 132 (Supplement 1): 3861.

https://doi.org/10.1182/blood-2018-99-117330

Published: 2018

Journal Articles

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

Torsten Kessler, MD, Steffen Koschmieder, MD, Christoph Schliemann, MD, Martina Crysandt, Jan-Henrik Mikesch, MD, Matthias Stelljes, MD, Linus Angenendt, Georg Lenz, Anna Kirsch, Kerstin Vehring, Hartmann Wolfgang, Eva Wardelmann, Eike Bormann, Joachim Gerss, Tim H. Brümmendorf, MD, Carsten Mueller-Tidow, Wolfgang E. Berdel, MD

Blood (2018) 132 (Supplement 1): 5176.

https://doi.org/10.1182/blood-2018-99-118095

Published: 2018

Journal Articles

The HLA Ligandome Landscape of Chronic Myeloid Leukemia Delineates Novel T-Cell Epitopes for Immunotherapy

Blood (2018) 132 (Supplement 1): 4243.

https://doi.org/10.1182/blood-2018-99-113376

Published: 2018

Journal Articles

Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN)

Blood (2018) 132 (Supplement 1): 4292.

https://doi.org/10.1182/blood-2018-99-112377

Published: 2018

NARROW

Bosutinib (BOS) Versus Imatinib for Newly Diagnosed Chronic Phase (CP) Chronic Myeloid Leukemia (CML): Final 5-Year Results from the Bfore Trial

Prevalence of Inherited Predisposition Syndromes in Young Patients with Acute Myeloid Leukemia and Aberrant Karyotype

Interplay between PI3K/mTOR Signaling and IRE1a-XBP1 Promotes Survival of Pre-B NRAS G12D all Cells Providing a Therapeutic Vulnerability for the "Undruggable" Driver RAS

Long-Term Cardiac, Vascular, and Hypertension Safety of Bosutinib (BOS) Versus Imatinib (IMA) for Newly Diagnosed Chronic Myeloid Leukemia (CML): Results from the Bfore Trial

High-Risk Additional Chromosomal Abnormalities in CML Herald Death By Blast Crisis Already at Low Blast Levels

Efficacy of Bosutinib in Imatinib-Resistant Vs Dasatinib/Nilotinib-Resistant Chronic Phase Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Time from Diagnosis to Treatment Does Not Affect Outcome in Intensively Treated Patients with Newly Diagnosed Acute Myeloid Leukemia

Genotypes of the Gene Encoding the Membrane Transporter SLC22A4 Are Associated with Molecular Relapse-Free Survival after Discontinuation of Imatinib Therapy in Patients with Chronic Myeloid Leukemia

STAT1 Transcriptional Response Predicts Molecular Responses of PB-Derived Clonogenic Cells from MPN Patients to Interferon Alpha

Efficacy and Safety of Bosutinib By Charlson Comorbidity Index in Previously Treated Patients with Chronic Myeloid Leukemia: Results from the Phase 4 BYOND Study

Ruxolitinib Shows Efficacy in Patients with Newly-Diagnosed Polycythemia Vera: Futility Analysis of the Randomized Ruxo-BEAT Clinical Trial of the German Study Group for Myeloproliferative Neoplasms

Deconstructing the Clonal Advantage and Clonal Stability of 5q- Candidate Genes in Del(5q) MDS on a Single Cell Level

Maintenance of Health-Related Quality of Life in the Phase 4 BYOND Study of Bosutinib for Pretreated Chronic Phase Chronic Myeloid Leukemia

Common Variable Immunodeficiency (CVID) in Adults As First Manifestation of (cryptic) Dyskeratosis Congenita

Androgen Derivatives Improve Blood Counts and Elongate Telomere Length in Patients with Dyskeratosis Congenita

Comparison of Fluorescence in Situ Hybridization and Flow Cytometry (Flow-FISH) with Monochrome Multiplex Quantitative Polymerase Chain Reaction (MM-qPCR) for Telomere Length Screening in Adult Patients with Suspected Cryptic Dyskeratosis Congenita (DKC)

Phase II Pilot Clinical Trial of Pazopanib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When No Intensive Treatment Is Possible

The HLA Ligandome Landscape of Chronic Myeloid Leukemia Delineates Novel T-Cell Epitopes for Immunotherapy

Comorbidities Such As Thromboembolic Events Significantly Worsen Patient-Reported Quality of Life (QoL) and Symptoms in Myeloproliferative Neoplasms (MPN) - Data from the Bioregistry of the German Study Group for MPN (GSG-MPN)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only